Ultragenyx Pharmaceutical Newsroom

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire16:30 ET

Express News | Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Reuters16:30 ET

Wells Fargo Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $88

Moomoo News14:35 ET · Ratings

Wells Fargo Remains a Buy on Ultragenyx Pharmaceutical (RARE)

TipRanks13:39 ET · Ratings

Evercore Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $70

Moomoo News13:31 ET · Ratings

Express News | Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $88

BenzingaDec 20 08:38 ET

NHS England Rolls Out Evkeeza ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older With Homozygous Familial Hypercholesterolaemia (HoFH)

GlobeNewswireDec 20 03:00 ET

Express News | Ultragenyx Pharmaceutical Inc - Primary Endpoint Is Improvement in Cognition Assessed by Bayley-4

ReutersDec 19 16:06 ET

Express News | Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating Gtx-102 in Angelman Syndrome

ReutersDec 19 16:05 ET

Express News | Ultragenyx Submits Biologics License Application to the U.S. FDA for Ux111 Aav Gene Therapy for the Treatment of Sanfilippo Syndrome Type a (Mps Iiia)

ReutersDec 19 08:00 ET

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

GlobeNewswireDec 19 08:00 ET

Express News | Ultragenyx Pharmaceutical Inc : Jefferies Cuts Target Price to $123 From $124

ReutersDec 17 01:05 ET

Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81

Moomoo NewsDec 16 06:31 ET · Ratings

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Bicycle Therapeutics (BCYC) and Quest Diagnostics (DGX)

TipRanksDec 16 06:30 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Ultragenyx Pharmaceutical (RARE) and Henry Schein (HSIC)

TipRanksDec 16 01:40 ET · Ratings

Insider Sale: President & CEO of $RARE (RARE) Sells 8,273 Shares

Quiver QuantitativeDec 11 18:47 ET

TD Cowen Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TipRanksDec 11 05:48 ET · Ratings

Mereo Stock Gains as Jefferies Starts Coverage With Buy Rating

Seeking AlphaDec 6 12:10 ET

Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Business And Shares Still Trailing The Industry

Simply Wall StDec 4 12:57 ET

Ultragenyx to Participate in Investor Conferences in December

GlobeNewswireNov 26 16:30 ET